Yahoo
Paris - Delayed Quote EUR

genOway Société anonyme (ALGEN.PA)

2.0400 -0.0300 (-1.45%)
As of 2:32:03 PM GMT+1. Market Open.
Chart Range Bar
Loading chart for ALGEN.PA
  • Previous Close 2.0700
  • Open 2.0500
  • Bid --
  • Ask --
  • Day's Range 2.0200 - 2.0600
  • 52 Week Range 2.0100 - 2.8800
  • Volume 6,306
  • Avg. Volume 6,018
  • Market Cap (intraday) 25.171M
  • Beta (5Y Monthly) 0.44
  • PE Ratio (TTM) --
  • EPS (TTM) -0.1500
  • Earnings Date --
  • Forward Dividend & Yield -- (0.00%)
  • Ex-Dividend Date --
  • 1y Target Est --

genOway Société anonyme, a biotechnology company, engages in the development and commercialization of custom genetically modified mouse, rat, and cell line models worldwide. It produces customized mouse models, such as knockout (KO) and knockin (KI) mouse models; customized rat models, including constitutive and conditional KO, point mutation KI, and quick KI rat models; and customized cell lines, such as constitutive and inducible KO, point mutation KI, reporter KI, quick KI, and KI cell lines. The company also offers humanized immune checkpoint mouse models; immunodeficient and reconstituted mouse and rat strains models; humanized immune target models; other mouse and rat catalog models; and cell lines. It serves pharmaceutical and life science companies, and academic institutes. The company was incorporated in 1999 and is based in Lyon, France.

www.genoway.com

--

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Recent News

View More

Performance Overview

Trailing total returns as of 11/2/2026, which may include dividends or other distributions. Benchmark is CAC 40 (^FCHI) .

YTD Return

ALGEN.PA
24.72%
CAC 40 (^FCHI)
1.83%

1-Year Return

ALGEN.PA
25.55%
CAC 40 (^FCHI)
1.49%

3-Year Return

ALGEN.PA
49.75%
CAC 40 (^FCHI)
13.31%

5-Year Return

ALGEN.PA
55.75%
CAC 40 (^FCHI)
15.50%

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -8.53%

  • Return on Assets (ttm)

    -2.06%

  • Return on Equity (ttm)

    -10.35%

  • Revenue (ttm)

    24.58M

  • Net Income Avi to Common (ttm)

    -2.1M

  • Diluted EPS (ttm)

    -0.1500

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    3.3M

  • Total Debt/Equity (mrq)

    68.83%

  • Levered Free Cash Flow (ttm)

    -4.13M

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: